Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aldeyra Therapeu (NQ: ALDX ) 5.070 -0.180 (-3.43%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Aldeyra Therapeu < Previous 1 2 3 4 5 6 Next > Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights August 05, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights July 29, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial July 12, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap July 11, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference June 09, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease June 08, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease June 07, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease May 24, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference May 23, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness May 18, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights May 05, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting May 04, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces Chief Financial Officer Transition April 28, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights April 27, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting April 21, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease April 05, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day March 29, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022 March 22, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights March 17, 2022 From Aldeyra Therapeutics, Inc Via Business Wire Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference March 14, 2022 From Aldeyra Therapeutics Via Business Wire Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference February 10, 2022 From Aldeyra Therapeutics Via Business Wire Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model February 01, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra® January 11, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference January 06, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy January 04, 2022 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease December 20, 2021 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Participate in Upcoming Conferences November 09, 2021 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance November 09, 2021 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease November 02, 2021 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights October 28, 2021 From Aldeyra Therapeutics, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.